BRPI0909179A2 - Composição farmacêutica, e, método de tratamento de uma doença autoimune. - Google Patents

Composição farmacêutica, e, método de tratamento de uma doença autoimune.

Info

Publication number: BRPI0909179A2
Authority: BR; Brazil
Prior art keywords: treatment; pharmaceutical composition; autoimmune disease; autoimmune; disease
Prior art date: 2008-03-13

Application number

BRPI0909179-3A

Other languages

English (en)

Inventor

Silke Aigner

Matthias Germer

Frank Osterroth

Christoph Uherek

Elmar Kraus

Andrea Wartenberg-Demand

Daniele Wolf

Sibylle Kaiser

Juergen Lindner

Christoph Bruecher

Benjamin Daelken

Original Assignee

Biotest Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-13

Filing date

2009-03-10

Publication date

2015-08-25

2008-03-13 Priority claimed from GB0804687A external-priority patent/GB0804687D0/en

2008-09-29 Priority claimed from GB0817809A external-priority patent/GB0817809D0/en

2009-03-10 Application filed by Biotest Ag filed Critical Biotest Ag

2015-08-25 Publication of BRPI0909179A2 publication Critical patent/BRPI0909179A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0909179-3A 2008-03-13 2009-03-10 Composição farmacêutica, e, método de tratamento de uma doença autoimune. BRPI0909179A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0804687A GB0804687D0 (en)	2008-03-13	2008-03-13	Humanized antibody
GB0817809A GB0817809D0 (en)	2008-09-29	2008-09-29	Agent for treating disease
PCT/EP2009/052810 WO2009112502A1 (en)	2008-03-13	2009-03-10	Agent for treating disease

Publications (1)

Publication Number	Publication Date
BRPI0909179A2 true BRPI0909179A2 (pt)	2015-08-25

Family

ID=40756668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909179-3A BRPI0909179A2 (pt)	2008-03-13	2009-03-10	Composição farmacêutica, e, método de tratamento de uma doença autoimune.

Country Status (16)

Country	Link
US (1)	US9550831B2 (pt)
EP (1)	EP2260057B1 (pt)
JP (2)	JP5604311B2 (pt)
KR (1)	KR20100135808A (pt)
CN (1)	CN102027018A (pt)
AU (1)	AU2009224690B2 (pt)
BR (1)	BRPI0909179A2 (pt)
CA (1)	CA2717812A1 (pt)
CO (1)	CO6311008A2 (pt)
CR (1)	CR11723A (pt)
ES (1)	ES2610327T3 (pt)
IL (1)	IL207892A0 (pt)
MX (1)	MX2010010027A (pt)
RU (1)	RU2540018C2 (pt)
SG (1)	SG190627A1 (pt)
WO (1)	WO2009112502A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7832566B2 (en)	2002-05-24	2010-11-16	Biomet Biologics, Llc	Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20060278588A1 (en)	2002-05-24	2006-12-14	Woodell-May Jennifer E	Apparatus and method for separating and concentrating fluids containing multiple components
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
US8034014B2 (en)	2007-03-06	2011-10-11	Biomet Biologics, Llc	Angiogenesis initation and growth
US20080269762A1 (en) *	2007-04-25	2008-10-30	Biomet Manufacturing Corp.	Method and device for repair of cartilage defects
US8753690B2 (en) *	2008-02-27	2014-06-17	Biomet Biologics, Llc	Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en)	2008-02-27	2016-07-20	Biomet Biologics, LLC	Interleukin-1 receptor antagonist rich solutions
PL2262838T3 (pl) *	2008-03-13	2016-10-31		Środek do leczenia choroby
CN102027017A (zh) *	2008-03-13	2011-04-20	生物测试股份公司	一种治疗疾病的试剂
BRPI0919489A2 (pt)	2008-09-29	2015-12-01	Biotest Ag	composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato
WO2011031553A2 (en)	2009-08-27	2011-03-17	Biomet Biologics, Llc	Implantable device for production of interleukin-1 receptor antagonist
US20110052561A1 (en) *	2009-08-27	2011-03-03	Biomet Biologics,LLC	Osteolysis treatment
GB0920944D0 (en) *	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
JP2013536841A (ja)	2010-09-03	2013-09-26	バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニー	インターロイキン−１受容体アンタゴニストを送達するための方法および組成物
EP2683395B2 (en)	2011-03-11	2026-05-20	Hopitaux Paris Assist Publique	USE OF LOW-DOSE IL-2 FOR THE TREATMENT OF TYPE 1 DIABETIC DISORDERS
ES2811624T3 (es)	2011-03-11	2021-03-12	Hopitaux Paris Assist Publique	Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
US9758806B2 (en)	2013-03-15	2017-09-12	Biomet Biologics, Llc	Acellular compositions for treating inflammatory disorders
US9950035B2 (en)	2013-03-15	2018-04-24	Biomet Biologics, Llc	Methods and non-immunogenic compositions for treating inflammatory disorders
US10208095B2 (en)	2013-03-15	2019-02-19	Biomet Manufacturing, Llc	Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en)	2013-03-15	2018-12-04	Biomet Biologics, Llc	Treatment of pain using protein solutions
US20140271589A1 (en)	2013-03-15	2014-09-18	Biomet Biologics, Llc	Treatment of collagen defects using protein solutions
US9878011B2 (en)	2013-03-15	2018-01-30	Biomet Biologics, Llc	Treatment of inflammatory respiratory disease using biological solutions
US9895418B2 (en)	2013-03-15	2018-02-20	Biomet Biologics, Llc	Treatment of peripheral vascular disease using protein solutions
EP3074507B1 (en)	2013-11-26	2022-01-05	Biomet Biologics, LLC	Methods of mediating macrophage phenotypes
RU2016139006A (ru)	2014-03-05	2018-04-05	Юсб Биофарма Спрл	Мультимерные fc-белки
EP3114137A1 (en) *	2014-03-05	2017-01-11	UCB Biopharma SPRL	Multimeric fc proteins
US10441635B2 (en)	2014-11-10	2019-10-15	Biomet Biologics, Llc	Methods of treating pain using protein solutions
EP3261651B1 (en) *	2015-02-27	2022-05-04	iCell Gene Therapeutics LLC	Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US9763800B2 (en)	2015-03-18	2017-09-19	Biomet C. V.	Implant configured for hammertoe and small bone fixation
RU2727900C2 (ru) *	2016-02-26	2020-07-24	ЭсСиЭм ЛАЙФСАЙЕНС КО., ЛТД.	Фармацевтическая композиция для предотвращения или лечения заболеваний, опосредованных регуляторными т-клетками
IT202100025427A1 (it)	2021-10-04	2023-04-04	S&R Farm S P A	Uso di una combinazione topica e sistemica per il trattamento di disordini immunologici cutanei legato allo squilibrio della popolazione Treg residente

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT90657B (pt)	1988-05-27	1995-03-01	Ortho Pharma Corp	Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
JPH0768273B2 (ja)	1988-12-02	1995-07-26	カルピス食品工業株式会社	抗ｈｉｖペプチド
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU5656890A (en)	1989-05-02	1990-11-29	Genelabs Incorporated	Chemically modified cd4 peptide fragments having anti-retroviral properties
US5690933A (en) *	1989-05-31	1997-11-25	Glaxo Wellcome Inc.	Monoclonal antibodies for inducing tolerance
GB8912497D0 (en)	1989-05-31	1989-07-19	Cobbold Stephen P	Monoclonal antibodies
US20020099179A1 (en) *	1989-12-21	2002-07-25	Linda K. Jolliffe	Cdr-grafted antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
HUT60768A (en)	1990-03-16	1992-10-28	Sandoz Ag	Process for producing cd25 fixing molecules
US7084260B1 (en) *	1996-10-10	2006-08-01	Genpharm International, Inc.	High affinity human antibodies and human antibodies against human antigens
AU662891B2 (en) *	1990-11-27	1995-09-21	Biogen Idec Ma Inc.	Anti CD-4 antibodies blocking HIV-induced syncytia
US7192584B2 (en) *	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) *	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5777085A (en) *	1991-12-20	1998-07-07	Protein Design Labs, Inc.	Humanized antibodies reactive with GPIIB/IIIA
IL101769A (en)	1992-05-03	2007-02-11	Yeda Res & Dev	Modulation of TNF receptor action
US6270766B1 (en) *	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1994008619A1 (en)	1992-10-08	1994-04-28	The Kennedy Institute Of Rheumatology	Treatment of autoimmune and inflammatory disorders
WO1995009652A1 (en)	1993-10-06	1995-04-13	The Kennedy Institute For Rheumatology	Treatment of autoimmune and inflammatory disorders
EP0614984B2 (en) *	1993-03-05	2010-11-03	Bayer HealthCare LLC	Anti-TNF alpha human monoclonal antibodies
EP0631783A1 (en)	1993-06-03	1995-01-04	Mitsubishi Chemical Corporation	Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) *	1994-03-10	2002-06-06	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
EP1161955A3 (en)	1995-05-18	2001-12-19	Ortho Pharmaceutical Corporation	Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
HU230048B1 (hu)	1996-02-09	2015-06-29	Abbvie Biotechnology Ltd	Humán TNFalfa-kötő antitestek alkalmazása
US20010056066A1 (en) *	1996-07-26	2001-12-27	Smithkline Beecham Corporation	Method of treating immune cell mediated systemic diseases
WO1998014211A1 (en)	1996-10-01	1998-04-09	Celltech Therapeutics Limited	Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
US6037454A (en) *	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
DE19722888A1 (de) *	1997-05-28	1998-12-03	Thomas Prof Dr Huenig	Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
AU3633000A (en)	1999-03-26	2000-10-16	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
EP1194167B1 (en) *	1999-06-09	2009-08-19	Immunomedics, Inc.	Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU6941000A (en)	1999-08-27	2001-03-26	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
US7304127B2 (en)	1999-08-27	2007-12-04	United States Of America As Represented By The Secretary, Department Of Health And Human Services	Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU2001275186A1 (en) *	2000-06-02	2001-12-17	Nicole Kirchhof	Immunotherapeutic method to prevent islet cell rejection
US20020058029A1 (en) *	2000-09-18	2002-05-16	Nabil Hanna	Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
DE10050935A1 (de) *	2000-10-11	2002-05-02	Tegenero Gmbh	Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
RU2285541C2 (ru) *	2000-12-22	2006-10-20	Байоджен Айдек Инк.	Комбинированная терапия для лечения аутоиммунных заболеваний с использованием комбинации элиминирующего в-клетки/иммунорегуляторного антител
AU2002249958B2 (en)	2001-01-16	2007-11-08	Vascular Therapies, Inc.	Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
CA2440649A1 (en) *	2001-03-07	2002-09-19	Children's Medical Center Corporation	Method to screen peptide display libraries using minicell display
EP1241249A1 (en)	2001-03-12	2002-09-18	Gerold Schuler	CD4+CD25+regulatory T cells from human blood
ES2366775T3 (es)	2001-04-24	2011-10-25	Merck Patent Gmbh	POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
US7541443B2 (en)	2001-06-14	2009-06-02	Tolerrx, Inc.	Anti-CD4 antibodies
EP1395284B1 (en)	2001-06-14	2010-12-08	Isis Innovation Limited	Non-depleting anti-CD4 antibody TRX1 and its uses
GB2376466A (en)	2001-06-14	2002-12-18	Mark Frewin	TRX1 antibody
DK1451224T3 (da) *	2001-12-04	2012-11-19	Theramab Llc	Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien
DE10212108A1 (de) *	2002-03-13	2003-10-02	Tegenero Ag	Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) *	2002-07-04	2004-01-22	Tegenero Ag	Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
EP1578364A4 (en)	2002-09-16	2011-06-08	Genentech Inc	COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
US7388079B2 (en)	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
US7501494B2 (en) *	2003-01-15	2009-03-10	United Biomedical, Inc.	Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en) *	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
SI1613350T1 (sl) *	2003-04-09	2009-08-31	Genentech Inc	Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
GB0314461D0 (en)	2003-06-20	2003-07-23	Isis Innovation	Suppression of transplant rejection
US7691970B2 (en)	2003-08-25	2010-04-06	Pieris Ag	Muteins of a bilin-binding protein with affinity for a given target
EP1600164A3 (de) *	2003-09-22	2006-05-17	TeGenero AG	Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) *	2003-11-11	2005-06-16	Tegenero Ag	Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
RU2007102055A (ru)	2004-06-22	2008-07-27	Толерркс, Инк. (Us)	Оптимизированное введение доз анти-cd4-антител для индукции толерантности у приматов
CN101031305A (zh) *	2004-09-29	2007-09-05	兴和株式会社	类风湿性关节炎的预防和/或治疗药物
EP2171060B1 (de)	2004-11-11	2013-10-02	TheraMAB LLC	Superagonistische anti-cd28 antikörper
WO2006055077A2 (en)	2004-11-12	2006-05-26	The University Of North Carolina At Charlotte	Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom
DE102004063494A1 (de) *	2004-12-23	2006-07-13	Tegenero Ag	Antikörper
JP4730733B2 (ja) *	2005-05-02	2011-07-20	国立大学法人京都大学	４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
AU2006267090B2 (en) *	2005-07-11	2013-03-07	Provention Bio, Inc.	Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2006281803B9 (en)	2005-08-18	2013-05-30	Genmab A/S	Therapy with CD4 binding peptides and radiation
RU2482132C2 (ru) *	2005-08-26	2013-05-20	Роше Гликарт Аг	Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
EP1973950B1 (en)	2006-01-05	2014-09-17	Genentech, Inc.	Anti-ephb4 antibodies and methods using the same
WO2007109052A2 (en) *	2006-03-16	2007-09-27	Genentech, Inc.	Methods of treating lupus using cd4 antibodies
EP2010569A4 (en)	2006-03-20	2009-09-09	Xoma Technology Ltd	HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
WO2007117602A2 (en)	2006-04-07	2007-10-18	Biogen Idec Ma Inc.	Isolation and use of human regulatory t cells
WO2007135684A2 (en)	2006-05-22	2007-11-29	Hadasit Medical Research Services & Development Limited	Method of treatment of anti-cd4 autoimmunity
US8557533B2 (en)	2007-02-01	2013-10-15	Helmut Jonuleit	Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
WO2008134046A1 (en)	2007-04-27	2008-11-06	Genentech, Inc.	Potent, stable and non-immunosuppressive anti-cd4 antibodies
PL2262838T3 (pl) *	2008-03-13	2016-10-31		Środek do leczenia choroby
CN102027017A (zh) *	2008-03-13	2011-04-20	生物测试股份公司	一种治疗疾病的试剂
EP2101173A1 (en)	2008-03-14	2009-09-16	Vivalis	In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
US8951793B2 (en)	2008-08-21	2015-02-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Method of making an isolated population of FOXP3+ regulatory T cells
ES2335381B1 (es)	2008-09-24	2011-02-28	Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron	Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
BRPI0919489A2 (pt) *	2008-09-29	2015-12-01	Biotest Ag	composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato

2009
- 2009-03-10 AU AU2009224690A patent/AU2009224690B2/en not_active Ceased
- 2009-03-10 MX MX2010010027A patent/MX2010010027A/es active IP Right Grant
- 2009-03-10 RU RU2010141822/10A patent/RU2540018C2/ru not_active IP Right Cessation
- 2009-03-10 SG SG2013034210A patent/SG190627A1/en unknown
- 2009-03-10 CN CN2009801173185A patent/CN102027018A/zh active Pending
- 2009-03-10 EP EP09720958.9A patent/EP2260057B1/en active Active
- 2009-03-10 BR BRPI0909179-3A patent/BRPI0909179A2/pt not_active Application Discontinuation
- 2009-03-10 CA CA2717812A patent/CA2717812A1/en not_active Abandoned
- 2009-03-10 KR KR1020107022912A patent/KR20100135808A/ko not_active Ceased
- 2009-03-10 WO PCT/EP2009/052810 patent/WO2009112502A1/en not_active Ceased
- 2009-03-10 ES ES09720958.9T patent/ES2610327T3/es active Active
- 2009-03-10 JP JP2010550182A patent/JP5604311B2/ja not_active Expired - Fee Related
2010
- 2010-08-31 IL IL207892A patent/IL207892A0/en unknown
- 2010-09-13 US US12/880,768 patent/US9550831B2/en active Active
- 2010-10-11 CR CR11723A patent/CR11723A/es not_active Application Discontinuation
- 2010-10-13 CO CO10127116A patent/CO6311008A2/es not_active Application Discontinuation
2014
- 2014-01-24 JP JP2014011246A patent/JP2014101369A/ja active Pending

Also Published As

Publication number	Publication date
IL207892A0 (en)	2010-12-30
JP5604311B2 (ja)	2014-10-08
CO6311008A2 (es)	2011-08-22
JP2011513465A (ja)	2011-04-28
SG190627A1 (en)	2013-06-28
RU2010141822A (ru)	2012-04-20
WO2009112502A1 (en)	2009-09-17
AU2009224690A1 (en)	2009-09-17
EP2260057B1 (en)	2016-11-23
MX2010010027A (es)	2011-05-02
CN102027018A (zh)	2011-04-20
RU2540018C2 (ru)	2015-01-27
ES2610327T3 (es)	2017-04-27
JP2014101369A (ja)	2014-06-05
WO2009112502A9 (en)	2010-01-07
EP2260057A1 (en)	2010-12-15
US9550831B2 (en)	2017-01-24
CR11723A (es)	2011-06-07
KR20100135808A (ko)	2010-12-27
CA2717812A1 (en)	2009-09-17
US20110059083A1 (en)	2011-03-10
AU2009224690B2 (en)	2014-10-09

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-14	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-01	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-01-28	B09B	Patent application refused [chapter 9.2 patent gazette]
2020-11-17	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
BRPI0909180A2 (pt)	2016-08-09	composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0909048A2 (pt)	2015-11-24	composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0814941A2 (pt)	2014-09-30	Composição de tratamentode semente, e, método de tratamento de semente.
BRPI1007477A2 (pt)	2016-02-16	método, e, composição de tratamento de poço
BRPI1013705A2 (pt)	2016-04-05	compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI0918652A2 (pt)	2015-08-25	Composições farmacêuticas e métodos de libração relacionadas.
BRPI0820139A2 (pt)	2014-09-30	Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
BRPI0922122A2 (pt)	2017-08-01	composições e métodos para tratamento de doença celíaca.
LT3205334T (lt)	2020-09-25	Būdas ir kompozicija, skirti akių hipertenzijai ir glaukomai gydyti
BRPI0915267A2 (pt)	2015-08-18	Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
BRPI0917358A2 (pt)	2015-11-17	formulação farmacêutica de liberação controlada e método.
BRPI0922440A2 (pt)	2018-10-23	dispositivo protético e método de fabricação do mesmo .
BRPI0923624A2 (pt)	2016-01-19	palmilha, e, métodos para montar uma palmilha, e para aliviar dor de artrite
BRPI1013559A2 (pt)	2016-04-12	compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
BRPI1010772A2 (pt)	2016-11-01	composto,e, composição farmacêutica.
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
BRPI1011423A2 (pt)	2016-03-15	composição injetável, kit e método cosmético.
BRPI0820474A2 (pt)	2017-05-23	método de tratamento de uma doença, uso de composto, e, composto
BRPI1009418A2 (pt)	2016-03-01	nanocapsula de proteina, metodo de pdroduzir uma nanocapsula, e metodo de distribuir uma proteina
HUE050319T2 (hu)	2020-11-30	Kompozíciók és eljárások alkoholfogyasztással kapcsolatos rendellenességek, fájdalom és más betegségek kezelésére
BR112013015796A2 (pt)	2017-03-21	composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
BRPI1006145A2 (pt)	2017-05-30	"composição e método para tratamento de diabetes".
BRPI0914410A2 (pt)	2016-08-16	composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
BRPI0822472A2 (pt)	2015-06-16	Método, camundongo, e, composição